Mitzi Nagarkatti to Enzyme Inhibitors
This is a "connection" page, showing publications Mitzi Nagarkatti has written about Enzyme Inhibitors.
Connection Strength
0.339
-
Exogenous PP2A inhibitor exacerbates the progression of nonalcoholic fatty liver disease via NOX2-dependent activation of miR21. Am J Physiol Gastrointest Liver Physiol. 2019 10 01; 317(4):G408-G428.
Score: 0.129
-
Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation. Brain Behav Immun. 2017 Jan; 59:10-20.
Score: 0.104
-
Higher intestinal and circulatory lactate associated NOX2 activation leads to an ectopic fibrotic pathology following microcystin co-exposure in murine fatty liver disease. Comp Biochem Physiol C Toxicol Pharmacol. 2020 Dec; 238:108854.
Score: 0.035
-
Role of Fas-Fas ligand interactions in 2,3,7,8-tetrachlorodibenzo- p-dioxin (TCDD)-induced immunotoxicity: increased resistance of thymocytes from Fas-deficient (lpr) and Fas ligand-defective (gld) mice to TCDD-induced toxicity. Toxicol Appl Pharmacol. 1999 Oct 15; 160(2):141-55.
Score: 0.033
-
Programming of neurotoxic cofactor CXCL-10 in HIV-1-associated dementia: abrogation of CXCL-10-induced neuro-glial toxicity in vitro by PKC activator. J Neuroinflammation. 2012 Oct 18; 9:239.
Score: 0.020
-
Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1. Cell Immunol. 2011; 271(2):392-400.
Score: 0.019